• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Varicose veins associated with higher risk of deep vein thromboses, pulmonary embolisms, and peripheral arterial disease

byDaniel Fisher
March 2, 2018
in Cardiology, Chronic Disease, Emergency, Imaging and Intervention, Public Health
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this case-control study, patients with varicose veins were at higher risk of deep vein thromboses (DVTs), pulmonary embolisms (PEs), and peripheral arterial disease (PAD).

2. Varicose veins inferred a greater increase in risk in younger patients for DVT and PAD, and men with varicose veins were at higher risk of PAD than women.

Evidence Rating Level: 2 (Good)

Study Rundown: Varicose veins is a highly prevalent disease in adults and is associated with increased inflammation in the vascular system. However, while some smaller cohort studies have tried to estimate the risk of other adverse vascular events and disease, a large cohort study has yet to be completed. In this Taiwanese, case-control cohort study, patients with varicose veins had a higher rate of Deep Vein Thromboses (DVTs), Pulmonary Embolisms (PEs), and Peripheral Arterial Disease (PAD). These results remained significant even when controlling for a number of other co-morbidities and risk factors. For DVT and PAD, varicose veins inferred a greater increase in risk in younger patients, and men with varicose veins were at higher risk of PAD than women. As a negative control, hemangioma was not associated with increased risk of DVT or PE but was associated with a slight decreased risk for PAD. Analysis estimating the potential effects of unmeasured confounders did support a possibility of unknown confounders influencing the association between varicose veins and PE and PAD, but the association with DVT remained robust.

The rigor and large sample size of this study greatly strengthen the conclusions of the study, though some limitations remain. The most important limitation concerns the retrospective nature of the study, and future prospective cohort studies with careful documentation of confounders, especially smoking, would be especially helpful in supporting this study’s conclusions.

Click to read the study, published in JAMA

RELATED REPORTS

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Relevant Reading: Persons With Varicose Veins Have a High Subsequent Incidence of Arterial Disease: A Population-Based Study in Tampere, Finland

In-Depth [case-control]: A total of 212 984 patients were analyzed from the National Health Insurance (NHI) program in Taiwan from 2001 to 2013, with a 4:1 control-to-varicose-vein, age- and sex-matched cohort. Patients were excluded if they were younger than 20 years of age or if they had a diagnosis of DVT, PE, or PAD prior to their varicose vein diagnosis or index date for age-matched controls. Control for the following confounding factors were included in the analysis: sex, age, index year, number of outpatient visits during the year before index date, and comorbidities including hypertension, diabetes, chronic obstructive pulmonary disease, hyperlipidemia, malignancy, heart failure, ischemic heart disease, stroke, and chronic renal insufficiency.

Validation of the varicose vein diagnosis revealed a positive predictive value (PPV) of 98% (CI95 0.95 to 0.99%) with a worse case PPV of 82% (CI95 0.77 to 0.87%). Varicose veins increased the risk of DVT (HR 5.30; CI95 5.05 to 5.56), PE (HR 1.73; CI95 1.54 to 1.94), and PAD (HR 1.72; CI95 1.68 to 1.77). For DVT and PAD, varicose veins inferred a greater increase in risk in younger patients, and men with varicose veins were at higher risk of PAD than women (p < 0.05). As a negative control, hemangioma was not associated with DVT (HR 1.09; CI, 0.99 to 1.20) or PE (HR 1.02; CI95 0.81 to 1.28) but was associated with a decreased risk for PAD (HR CI95 0.78 to 0.86). Analysis for two falsification endpoints, hyperlipidemia and lung cancer, were weakly associated with varicose veins (hyperlipidemia 1.20; CI95 1.19 to 1.22; lung cancer 0.81; CI95 0.76-0.86). Inverse probability of treatment weighting analysis was used to estimate the potential for unmeasured confounders to change risk ratios and supported a possibility of unknown confounders influencing the association between varicose veins and PE and PAD, but the association with DVT remained robust.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: peripheral artery diseasevaricose veinsvenous thromboembolism
Previous Post

Policy statement outlines ways to improve pediatric medication safety

Next Post

Meropenem-vaborbactam non-inferior to piperacillin-tazobactam for complicated urinary tract infections: The TANGO I trial

RelatedReports

Drug comparison trials collage: a brass balance scale with white tablets on one pan and gray capsules on the other
Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Hematology

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

May 20, 2025
#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
StudyGraphics

#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients

March 10, 2025
Next Post

Meropenem-vaborbactam non-inferior to piperacillin-tazobactam for complicated urinary tract infections: The TANGO I trial

Early diagnosis of HIV infection through analysis of oral fluid [Pre-Clinical]

Opioid-related pediatric ICU admissions on the rise over past decade

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early mitral valve surgery may improve long-term survival in asymptomatic severe mitral regurgitation
  • CDC reports increasing early-season influenza activity and at least 900 deaths nationwide
  • A concentrated exposure therapy intervention may be more effective than digital cognitive behavioural therapy in obsessive-compulsive disorder
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.